Hematology

Latest News

Despite the frequent potential for drug-drug interaction, exposure to CYP3A inducers or inhibitors was not linked to worse overall survival (OS) after adjusting for age, comorbidity, and dosing. | Image Credit: sovova - stock.adobe.com
Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL

September 16th 2025

Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.

Lori A. Leslie, MD | Image: John A. Theurer Cancer Center
Phase 2 Study Shows Feasibility of Axi-Cel Delivery in Outpatient Setting

September 13th 2025

The iRR6 may help identify those who are unlikely to derive long-term benefit from ruxolitinib and could be considered for alternative therapies. | Image credit: mdaros - stock.adobe.com
Refined iRR6 Model Improves Risk Stratification in Intermediate-1 Myelofibrosis

September 12th 2025

The study adds important data about how people with hematologic malignancies are affected by COVID-19 infection. | Image credit: Tyler Olson -stock.adobe.com
COVID-19 Risk Remains High for Patients With Hematologic Malignancies

September 10th 2025

While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com
Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

September 4th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com
April 18th 2025

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

Jared Kaltwasser
Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).
Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com
April 16th 2025

DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

Maggie L. Shaw
A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser
Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.
Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

Mary Caffrey Caspian Oliai, MD, MS Rose McNulty
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Andrew Kuykendall, MD
April 10th 2025

Rusfertide Cuts Phlebotomy Need in Polycythemia Vera: Andrew Kuykendall, MD

Maggie L. Shaw Andrew Kuykendall, MD
In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at Moffitt Cancer Center and VERIFY investigator, speaks to the impressive patient-reported outcomes seen thus far.
The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com
April 10th 2025

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com
April 8th 2025

Immune Microenvironment a Key Target in CLL

Jared Kaltwasser
A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).
Health equity concept | image credit: VectorMine - stock.adobe.com
April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).
CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com
April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw
In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
Targeting GPRC5D Holds Promise in Multiple Myeloma
April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser
Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.
Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser
The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.
Andrew Kuykendall, MD, Moffitt Cancer Center
April 1st 2025

Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation

Maggie L. Shaw Andrew Kuykendall, MD
In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable patients to live a more viable life and free them from being tethered to the need for regular phlebotomies.
FDA approval-Olivier Le Moal-stock.adobe.com
March 28th 2025

FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B

Giuliana Grossi
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi).
ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
March 28th 2025

ESA Treatment Improves OS in Lower-Risk MDS

Rose McNulty
Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival (OS) In lower-risk myelodysplastic syndromes (MDS), a new study found.
Ajai Chari, MD
March 27th 2025

Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM

Kyle Munz Ajai Chari, MD
For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.
ASH logo | images: ASH
March 24th 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

Mary Caffrey
The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.
CAR T | Image Credit: © Funny-stock.adobe.com
March 21st 2025

Overcoming CAR T Manufacturing Failure in LBCL

Maggie L. Shaw
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Woman taking pills from bottle | Image credit: Rawpixel.com – stock.adobe.com
March 20th 2025

In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib

Hayden E. Klein
A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.
Orca-T is manufactured with highly purified regulatory T cells, hematopoietic stem cells, and conventional T cells from peripheral blood from matched donors. | Image credit: fotogurmespb - stock.adobe.com.jpg
March 20th 2025

Orca-T Immunotherapy Improves cGVHD-Free Survival in ALL, AML, MDS

Rose McNulty
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who received standard allogeneic stem cell transplant for hematologic malignancies.
Andrew Kuykendall, MD, Moffitt Cancer Center
March 19th 2025

Understanding Hematocrit Thresholds in Polycythemia Vera Treatment

Maggie L. Shaw Andrew Kuykendall, MD
Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for men vs women.
CLL | Image credit: jarun011 – stock.adobe.com
March 19th 2025

Newer CLL Therapies Show Superior Long-Term Disease Control

Hayden E. Klein
Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.
Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute
March 17th 2025

Gene Editing for Safer CAR T-Cell Therapy in Large B-Cell Lymphoma

Maggie L. Shaw Frederick L. Locke, MD
Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma.
Modulating cholesterol metabolism in patients with CLL could improve T-cell function and possibly open up new therapeutic avenues to treat the disease. | Image credit: keetazalay - stock.adobe.com
March 11th 2025

Modulating Cholesterol Metabolism Could Open Therapeutic Pathways in CLL

Jared Kaltwasser
Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.
Fred Locke, MD, Moffitt Cancer Center and Research Institute
March 7th 2025

Overcoming Delays in CAR T for Large B-Cell Lymphoma

Maggie L. Shaw Frederick L. Locke, MD
Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen receptor (CAR) T-cell therapy, specifically allogeneic, which uses healthy donor cells.
Andrew Kuykendall, MD, Moffitt Cancer Center
March 5th 2025

Managing Polycythemia Vera to Reduce Risks and Improve Lives

Maggie L. Shaw Andrew Kuykendall, MD
Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells.
Ibrutinib tablets | Image credit: CLShebley – stock.adobe.com
March 5th 2025

Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better

Hayden E. Klein
Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.
BalanceIssues | Image Credit: © Bangkok Click Studio-stock.adobe.com
February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Sabarish Ayyappan, MD
February 27th 2025

Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies

Kyle Munz Sabarish Ayyappan, MD
More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.
Sabarish Ayyappan, MD
February 24th 2025

Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma

Kyle Munz Sabarish Ayyappan, MD
Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.
Frederick L. Locke, MD
February 24th 2025

Allogeneic vs Autologous CAR T-Cell Therapy Explained

Maggie L. Shaw Frederick L. Locke, MD
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy produced durable responses in relapsed/refractory large B-cell lymphoma.
<12345678
...
29>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo